Days
Hours
Minutes
Seconds
-40%
on all subscriptions*
Last days
Enjoy this offer
* See conditions under "Our services"

Valuation: BioRestorative Therapies, Inc.

Market Cap 8.98M 7.76M 7.15M 6.69M 12.54M 854M 12.73M 84.4M 32.91M 416M 33.71M 32.99M 1.44B P/E Ratio 2026 *
-0.71x
P/E Ratio 2027 * -0.87x
Enterprise Value 8.98M 7.76M 7.15M 6.69M 12.54M 854M 12.73M 84.4M 32.91M 416M 33.71M 32.99M 1.44B EV / Sales 2026 *
6.39x
EV / Sales 2027 * 3.88x
Free-Float
87.87%
Yield 2026 *
-
Yield 2027 * -
05-27 Kaos Capital acquires 4.9% stake in BioRestorative Therapies RE
05-26 BioRestorative Completes Dosing in Phase 2 Trial of BRTX-100 to Treat Chronic Lumbar Disc Disease; Shares Rise MT
05-26 Biorestorative Therapies says topline phase 2 data for BRTX-100 expected in Q2 2027 RE
05-26 BioRestorative Therapies, Inc. Completes Phase 2 Dosing Of BRTX-100 And Advances Lead Regenerative Spine Program Toward 2027 Topline Data CI
05-15 9,046,242 Common Stock of BioRestorative Therapies, Inc. are subject to a Lock-Up Agreement Ending on 15-MAY-2026. CI
05-15 Certain Series B Preferred Stock of BioRestorative Therapies, Inc. are subject to a Lock-Up Agreement Ending on 15-MAY-2026. CI
05-15 Certain Warrants of BioRestorative Therapies, Inc. are subject to a Lock-Up Agreement Ending on 15-MAY-2026. CI
05-15 Certain Options of BioRestorative Therapies, Inc. are subject to a Lock-Up Agreement Ending on 15-MAY-2026. CI
05-15 BioRestorative Therapies, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2026 CI
05-13 Biorestorative Therapies Presents New Preclinical Data on Source-Specific Exosome Functionality and Commercial Applications in Biocosmeceuticals CI
05-07 Biorestorative Therapies' BRTX-100 shows sustained pain & functional improvements in chronic lumbar disc disease RE
05-07 BioRestorative Therapies Reports Expanded Phase 2 Blinded Dataset for BRTX-100 Showing Sustained Pain and Functional Improvements in Chronic Lumbar Disc Disease CI
04-30 Biorestorative Therapies Inc Presents New Data at ISCT 2026 Highlighting Ongoing Phase 2 Clinical Trial in Chronic Lumbar Disease and Biocosmeceutical Platform CI
1 day-6.25%
1 week-12.96%
Current month-26.26%
1 month+78.48%
3 months+14.45%
6 months-68.24%
Current year-70.00%
1 week 0.35
Extreme 0.3496
0.42
1 month 0.16
Extreme 0.1593
0.68
Current year 0.16
Extreme 0.1593
1.28
1 year 0.16
Extreme 0.1593
1.89
3 years 0.16
Extreme 0.1593
7.13
5 years 0.16
Extreme 0.1593
34.4
10 years 0.16
Extreme 0.1593
20,040
Manager TitleAgeSince
Chief Executive Officer 55 16/11/2020
Director of Finance/CFO 59 04/11/2021
Chief Tech/Sci/R&D Officer 51 01/03/2012
Director TitleAgeSince
Director/Board Member 51 16/11/2020
Chairman 55 16/11/2020
Director/Board Member 53 18/03/2021
Date Insider Type Main position Quantity % Market Cap.
06/10/25Free

Chief Executive Officer

27,344 0.3427%
06/10/25Free

Chief Technology Officer

23,438 0.2938%
14/02/25Other

Chief Technology Officer

768,979 11.1125%
Change 5-day change 1-year change 3-year change Capi.($)
-6.25%-12.96%-82.38%-93.36% 8.98M
+1.03%+2.30%+54.92%+111.78% 56.42B
+2.72%+3.26%+47.26%+47.26% 44.54B
+1.12%+2.79%-13.71%-17.53% 22.9B
+1.17%+3.85%+1.00%+401.79% 21.21B
+3.81%-5.07%+12.00%-29.52% 16.4B
+0.15%+2.24%+9.10%-40.04% 15.4B
-0.69%+0.82%+27.17%+178.31% 13.35B
+5.27%+5.54%+14.25% - 12.36B
+1.61%+1.28%+92.88%+215.31% 11.15B
Average +0.99%+0.58%+16.25%+86.00% 21.37B
Weighted average by Cap. +1.72%+2.37%+31.92%+100.37%

Financials

2026 *2027 *
Net sales 1.4M 1.21M 1.12M 1.05M 1.96M 134M 1.99M 13.2M 5.15M 65M 5.27M 5.16M 225M 2.31M 2M 1.84M 1.72M 3.23M 220M 3.28M 21.73M 8.47M 107M 8.68M 8.49M 370M
Net income -13.52M -11.68M -10.76M -10.08M -18.88M -1.29B -19.17M -127M -49.55M -626M -50.75M -49.67M -2.17B -15.56M -13.44M -12.38M -11.59M -21.72M -1.48B -22.06M -146M -57.01M -720M -58.39M -57.15M -2.49B
Net Debt - -
Logo BioRestorative Therapies, Inc.
BioRestorative Therapies, Inc. is engaged in developing therapeutic products using cell and tissue protocols, primarily involving adult stem cells. The Company has two core programs that relate to the treatment of disc/spine disease and metabolic disorders. Its lead cell therapy candidate, BRTX-100, is a product formulated from autologous (or a person's own) cultured mesenchymal stem cells collected from the patient's bone marrow. It has commenced a Phase II clinical trial using BRTX-100 to treat chronic lower back pain arising from degenerative disc disease. The Company is engaged in developing a cell-based therapy candidate, ThermoStem Program, which targets obesity and metabolic disorders using brown adipose (fat) derived stem cells to generate brown adipose tissue (BAT). It has also licensed an investigational curved needle device designed to deliver cells and/or other therapeutic products or material to the spine and discs. It also operates a commercial biocosmeceutical platform.
Employees
14
Date Price Change Volume
12/06/26 0.3525 $ -6.25% 828,147
11/06/26 0.3760 $ -1.05% 439,162
10/06/26 0.3800 $ -3.65% 544,083
09/06/26 0.3944 $ +8.95% 1,025,853
08/06/26 0.3620 $ -10.62% 1,170,963
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
-
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
2
Last Close Price
0.3525USD
Average target price
8.000USD
Spread / Average Target
+2,169.50%

Quarterly revenue - Rate of surprise

  1. Stock Market
  2. Stocks
  3. BRTX Stock
- 40% : Our Best Subscriber-Only Tools to Spot Tomorrow’s Top Investments!
d
:
:
SEIZE THE OFFER!